Skip to main content

. 1985 Jul;52(1):105–109. doi: 10.1038/bjc.1985.156

Treatment of hepatocellular carcinoma with recombinant leucocyte interferon: a pilot study.

E Sachs, A M Di Bisceglie, G M Dusheiko, E Song, S F Lyons, B D Schoub, M C Kew

PMCID: PMC1977152 PMID: 2990514

107

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

Billiau A. The clinical value of interferons as antitumor agents. Eur J Cancer Clin Oncol. 1981 Sep;17(9):949–967. doi: 10.1016/s0277-5379(81)80001-6. [DOI] [PubMed] [Google Scholar]
Desmyter J., De Groote G., Ray M. B., Bradburne A. F., Desmet V., De Somer P., Alexander J. Tumorigenicity and interferon properties of the PLC/PRF/5 human hepatoma cell line. Prog Med Virol. 1981;27:103–108. [PubMed] [Google Scholar]
Kew M. C. The hepatitis-B virus and hepatocellular carcinoma. Semin Liver Dis. 1981 Feb;1(1):59–67. doi: 10.1055/s-2008-1063930. [DOI] [PubMed] [Google Scholar]
Shouval D., Rager-Zisman B., Quan P., Shafritz D. A., Bloom B. R., Reid L. M. Role in nude mice of interferon and natural killer cells in inhibiting the tumorigenicity of human hepatocellular carcinoma cells infected with hepatitis B virus. J Clin Invest. 1983 Aug;72(2):707–717. doi: 10.1172/JCI111020. [DOI] [PMC free article] [PubMed] [Google Scholar]

ACTIONS

RESOURCES